DailyIQ
|
Sector:Consumer DefensiveAll sectors
Last updated 4 minutes ago

CL·Colgate-Palmolive Company

$.
-. (-.%)
After Hours
High
$92.78
Open
$92.09
Market Cap
73.37B
52W High
$99.33
Low
$91.20
P. Close
$92.97
P/E
35.16
52W Low
$74.55
Fwd P/E
96.59
DailyIQ Est.
$97.56
Technical Score (1D)
55
BUY
News Sentiment
51
MIXED
Colgate‑Palmolive will host a live webcast of its Q2 2026 earnings call on July 31 at 8:30 a.m. ET, giving investors direct access to management’s guidance on growth drivers, margin dynamics, and strategic initiatives across its core segments. In the days leading up to the call, JP Morgan upgraded the stock to Overweight and lifted its price target to $104 from $96, while UBS similarly raised its target to $106 from $100, both reflecting confidence in steady earnings growth and margin expansion. These upgrades suggest that analysts expect the company’s recent 60.4 % gross margin and 17.8 % free‑cash‑flow margin to translate into continued profitability, which could support a higher valuation over the next 1–10 trading days. However, a margin‑growth debate has emerged, with analysts questioning whether raw‑material inflation and a shift toward higher‑margin oral‑care lines will offset the expected upside, implying that the current price may already be pricing in some of the anticipated gains. The debate highlights that any surprise in cost‑control or margin guidance during the earnings call could materially affect short‑term sentiment. Investors should watch the earnings webcast for clarity on margin expectations, especially how the company plans to manage rising input costs while maintaining pricing power. Additionally, monitoring consumer‑demand indicators, such as retail sales data and pet‑food market trends, will help gauge whether the company’s diversified product mix can sustain growth. Finally, keep an eye on the post‑call analyst revisions, as any adjustments to price targets or ratings will likely influence the stock’s trajectory in the coming days.
Earnings Summary
Colgate‑Palmolive, a global consumer‑goods company, focuses on oral, personal and home care and pet nutrition, delivering well‑known brands such as Colgate and Hill’s Science Diet through a broad retail network. In the last six quarters, the company has consistently outperformed earnings estimates, reporting EPS of 0.91 in Q4 2024, 0.91 in Q1 2025, 0.92 in Q2 2025, 0.91 in Q3 2025, 0.95 in Q4 2025 and 0.97 in Q1 2026, each beating the respective estimates of 0.889, 0.858, 0.895, 0.889, 0.940 and 0.957; revenue has trended upward from $4.944 B in Q4 2024 to $5.324 B in Q1 2026, with a brief dip in Q1 2025 followed by steady growth. Historically, the firm has maintained a 100 % EPS‑beat streak over the past year while revenue growth has remained positive, underscoring resilient demand across its core segments. The company’s robust distribution network and brand equity have helped sustain demand, while recent reports indicate organic revenue growth slowed to 3.6 % in the latest period, raising questions about the durability of the current upside. Analysts note that raw‑material inflation and a shift toward higher‑margin oral‑care lines could offset upside, making margin guidance a key focus. Recent analyst coverage highlights a margin‑growth debate, with JP Morgan and UBS upgrading the stock and raising price targets to $104 and $106, respectively, citing a 60.4 % gross margin and 17.8 % free‑cash‑flow margin; the upcoming Q2 2026 earnings webcast on July 31 is expected to clarify how the company plans to manage rising input costs and preserve pricing power, especially in the pet‑nutrition segment. Investors should watch for guidance on margin expectations, cost‑control initiatives, and any revisions to revenue or earnings forecasts, as these will shape short‑term sentiment and inform the next quarter’s performance outlook.

EPS

EstBeatMiss
$0.84$0.88$0.91$0.95$0.99Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$0.95 - -
Q1'26$0.96$0.97+1.4%
Q4'25$0.94$0.95+1.1%
Q3'25$0.89$0.91+2.4%
Q2'25$0.89$0.92+2.8%
Q1'25$0.86$0.91+6.1%

Revenue

EstBeatMiss
$4.8B$5.0B$5.2B$5.4B$5.6BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$5.5B - -
Q1'26$5.3B$5.3B-0.2%
Q4'25$5.3B$5.2B-0.8%
Q3'25 - $5.1B -
Q2'25 - $5.1B -
Q1'25 - $4.9B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

CL Stock Snapshot

CL is currently trading at $92.88, giving Colgate-Palmolive Company a market cap of 73.37B and a P/E ratio of 35.2. Today's range spans $91.20–$92.78, with shares opening at $92.09 and moving down $0.09 (0.1%) from the prior close. DailyIQ's technical score sits at 55/100 (HOLD) with a news sentiment reading of 51/100.

Over the past year CL has traded between $74.55 and $99.33 - the current price is +24.6% off the 52-week low and -6.5% from the high. 32 analysts cover the stock with a Buy consensus and a mean 12-month target of $96.20 (range $80.00–$105.00), implying upside of +3.6%.

Sector rotation context matters for CL's HOLD phase (55/100, HOLD): in Consumer Defensive, large-cap names (73.37B market cap) with neutral technicals and neutral sentiment (51/100) are often in a staging area ahead of a rotation trade. The current P/E ratio stands at 35.2. Price: $92.88 (in the upper portion of its 52-week range in $74.55–$99.33). When sector flows resume, names that consolidated cleanly rather than correcting sharply tend to lead the next leg - and CL's current setup fits that pattern.

In neutral phases, large-cap Consumer Defensive names like CL are often where sector rotation debates play out quietly — at 73.37B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 55/100 (HOLD) and neutral sentiment (51/100) at $92.88 (in the upper portion of its 52-week range) describe a stock that is being considered rather than avoided.